✦ LIBER ✦

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ Scribed by M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter Ryan; J. Sloan-Lancaster

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 182 KB
Volume: 62
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.27334

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of rheumatoid arthritis with h

Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

✍ Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Sh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

## Abstract ## Objective Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates the immune response, inflammation, and hematopoiesis. Overproduction of IL‐6 plays pathologic roles in rheumatoid arthritis (RA), and the blockade of IL‐6 may be therapeutically effective for the disease. This s

Anti–interleukin-6 receptor antibody the

Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study

✍ Rainer H. Straub; Peter Härle; Seizo Yamana; Takemasa Matsuda; Kiyoshi Takasugi; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

Therapeutic benefit of blocking interleu

Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

✍ E. H. S. Choy; D. A. Isenberg; T. Garrood; S. Farrow; Y. Ioannou; H. Bird; N. Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 1 views

Ofatumumab, a human anti-CD20 monoclonal

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 1 views

MLN3897 plus methotrexate in patients wi

MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study

✍ Clarissa E. Vergunst; Danielle M. Gerlag; Lisa von Moltke; Michael Karol; Tim Wy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## Objective To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX). ## Methods In this phase IIa, proof‐of‐concept study, patients meeting the

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views